New drug SLN12140 aims to control PNH in early trial
NCT ID NCT07387302
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tests the drug SLN12140 in 10 adults with PNH who have never taken complement inhibitors. The goal is to see if SLN12140 can reduce red blood cell destruction (measured by LDH levels) and improve hemoglobin. Participants receive different doses over 12 to 64 weeks, and the study monitors safety and how the drug works in the body.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SLN12140
- What this could lead to
- If it works, this could point toward a new treatment option for people with PNH to control red blood cell destruction without needing existing complement inhibitors.
- What could go wrong
- This is a very small early-phase trial with only 10 participants, so results may not apply to everyone. The drug may not work as hoped or could have unexpected side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, PNH are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new pill tame a rare blood disease? early safety trial begins
- New drug pegcetacoplan tested in teens with rare blood disorder
- New PNH drug VSA012 enters early human testing
- New pill CMS-D017 enters first human safety trials
- Thousands with blood diseases to be tracked in massive chinese registry
- New siRNA drug ADX-038 enters human trials for PNH anemia